Adaptive Biotechnologies reported Q2 2025 revenues of $58.9 million, marking a 36% increase year over year, mainly driven by robust demand for its clinical and pharmaceutical minimal residual disease (MRD) testing services via the ClonoSeq assay. The MRD segment accounted for 85% of revenues, with significant growth in test volume and average sales price. The company narrowed net loss and improved operational efficiency, reflecting strong market uptake and expanded pricing agreements across oncology indications.